Pharmaceutical major Lupin Ltd posted 25 per cent rise in net profit at Rs 140.10 crore during the first quarter of the current fiscal as compared to Rs 112 crore in the corresponding quarter of the previous year.
Net sales of the company rose by 26 per cent to Rs 1085.60 crore from Rs 862.30 crore in the quarter under review.
Advanced markets formulations sales (including US, Europe and Japan) increased 41 per cent to Rs 485.80 crore which contributed 45 per cent of the net sales for the quarter. Formulation sales in the US and EU grew by 40 per cent to Rs 355.10 crore from Rs 253.00 crore.
Lupin remained the fastest growing generic players in the US by prescriptions and the 9th largest in terms of overall prescription base. The company ranks in the Top 3, in 18 out of 22 generic products in the US market with market leadership (No 1) in 8 of these products.
Overall EU formulations sales including Hornosan grew by 101 per cent to Rs 41.30 crore from Rs 20.60 crore.
